Harter, P., Marmé, F., Redondo, A., Reuss, A., Lindemann, K., Kurzeder, C., . . . Pautier, P. (2026). Atezolizumab with bevacizumab and nonplatinum chemotherapy for recurrent ovarian cancer: Final results from the placebo-controlled AGO-OVAR 2.29/ENGOT-ov34 phase III trial : gynecologic cancer. Journal of clinical oncology, 44(2), . https://doi.org/10.1200/JCO-25-01210
Chicago-Zitierstil (17. Ausg.)Harter, Philipp, et al. "Atezolizumab with Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results from the Placebo-controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial : Gynecologic Cancer." Journal of Clinical Oncology 44, no. 2 (2026). https://doi.org/10.1200/JCO-25-01210.
MLA-Zitierstil (9. Ausg.)Harter, Philipp, et al. "Atezolizumab with Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results from the Placebo-controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial : Gynecologic Cancer." Journal of Clinical Oncology, vol. 44, no. 2, 2026, https://doi.org/10.1200/JCO-25-01210.